House-dust-mite SLIT tablet,
does it really help with Reduced combined allergic-rhinitis symptoms and rescue-medication use?
research showsThe grade is C. In 992-participant European MT-06, the final eight-week symptom-plus-medication score was 5.71 with 12 SQ-HDM versus 6.81 with placebo: difference -1.09 (95% CI -1.84 to -0.35). Approximate standardization from the interval and sample sizes gives Cohen d near 0.22, below the 0.5 medium-effect convention. Overall withdrawal was 20.7% and differential, 24.2% active versus 17.2% placebo, giving C with 46 points.
ads claimACARIZAX 12 SQ-HDM is a prescription product in Korea and should be initiated after confirming mite allergy and clinical suitability. It is not an over-the-counter wellness tablet; first dosing requires supervision capable of managing a severe allergic reaction.
Useful facts when choosing a product
- 12 SQ-HDM contains allergen extracts from D. pteronyssinus and D. farinae in a rapidly dissolving sublingual tablet.
- TCRS combines rhinitis symptom and rescue-medication scores.
- Pivotal MT-06 and P001 evidence came from the ALK-Merck development ecosystem.
Chamgap Semantic Classification Code
Candidate index · review held
S.12-sq-hdm-house-dust-mite-sublingual-immunotherapy-tablet.sublingual.combined-allergic-rhinitis-symptoms-and-rescue-medication-use.reduce.placeboSupplements and nutraceuticals > 12 SQ-HDM house-dust-mite sublingual immunotherapy tablet > Sublingual > combined allergic-rhinitis symptoms and rescue-medication use > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
MT-06 randomized 992 European adults to placebo (338), 6 SQ-HDM (336), or 12 SQ-HDM (318) for about 52 weeks. Overall withdrawal was 205/992 (20.7%), with differential loss of 77/318 (24.2%) on 12 SQ-HDM versus 58/338 (17.2%) on placebo. This differential withdrawal is the avoidable defect. Participants, investigators, and sponsor staff were blinded. P001 was directionally consistent but remained in the ALK-Merck development network. Manufacturer relationships were used only for independence and were not counted again as a withdrawal defect. MT-06 states 'Supported by ALK, Hørsholm, Denmark.'
Why this is classified as C (46)
The one-year placebo contrast was approximately d=0.22, below Cohen's medium-effect convention, and overall 20.7% differential withdrawal gives C with 46 points.
Counterpoint. A modest average effect may still matter to selected patients with medication-resistant symptoms, but it does not establish that a validated clinical threshold was exceeded.
Rejudgment record. Cross-check applied — Approximate Cohen d 0.22 for TCRS and differential withdrawal of 20.7% overall, 24.2% active versus 17.2% placebo; regulatory gates excluded as grade grounds
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E~ | Statistically positive but below the threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced combined symptom-plus-medication score | C | The difference was -1.09 points, a 16.1% reduction and approximate d of 0.22. |
| Reduced rhinitis symptom score | C | Observed-data relative reduction was 16.2%. |
| Reduced rescue-medication score | C | Observed-data relative reduction was 21.4%, with a wide 3.2% to 36.6% interval. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Demoly et al. MT-06 2016 | Double-blind three-arm placebo-controlled phase 3 trial in 12 European countries | 992: placebo 338, 6 SQ-HDM 336, 12 SQ-HDM 318; full analysis with multiple imputation | Paper wording: 'Supported by ALK, Hørsholm, Denmark.' | Primary: average TCRS during the final eight weeks of one-year treatment | 12 SQ-HDM 5.71 versus placebo 6.81; difference -1.09 (95% CI -1.84 to -0.35), relative reduction 16.1% (5.7% to 25.8%) | Pivotal manufacturer trial; the regulatory 20% gate was not used for grading |
| Nolte et al. P001 2016 | North American double-blind placebo-controlled phase 3 trial | 1,482 randomized; label analysis 566 active and 620 placebo | Merck & Co./ALK-Abelló development program | Primary: average TCRS during the final eight weeks | 4.10 versus 4.95; difference -0.80, relative reduction 17.2% (95% CI 9.7% to 25.0%) | Directionally consistent trial from the same manufacturer ecosystem |
Receipt — 5 References
All 5 cited sources were verified for existence at the original page (as of 2026-08-08).
Final verification and publication gate: Codex · Evidence date: 2026-08-08 · Corrections: none
Cite this verdict
[Chamgap] House-dust-mite SLIT tablet x reduced rhinitis symptoms and rescue medication — Evidence Grade C·46. 5 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/house-dust-mite-slit-tablet-allergic-rhinitis-score/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.